Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Efficacy, Safety and Immunogenicity Study of GSK Biologicals' Herpes Zoster Vaccine GSK1437173A in Adults Aged 70 Years or Older

Next Previous
Trial Profile

Efficacy, Safety and Immunogenicity Study of GSK Biologicals' Herpes Zoster Vaccine GSK1437173A in Adults Aged 70 Years or Older

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 30 Aug 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs GSK 137173A (Primary)
  • Indications Herpes zoster; Postherpetic neuralgia; Varicella zoster virus infections
  • Focus Registrational; Therapeutic Use
  • Acronyms ZOE-70
  • Sponsors GlaxoSmithKline; GSK

Most Recent Events

  • 25 Oct 2020 Results assessing vaccine efficacy (VE) of the adjuvanted recombinant zoster vaccine from NCT01165177, NCT01165229 and NCT01610414 presented at the IDWeek 2020.
  • 23 Mar 2018 According to a GlaxoSmithKline media release, European Commission and the Japanese Ministry of Health, Labour and Welfare (MHLW) has approved Shingrix for the prevention of shingles (herpes zoster) and post-herpetic neuralgia (PHN), the most common and often painful shingles-related complication, in adults aged 50 years or older.
  • 26 Feb 2018 Results of pooled data from two trials (NCT01165177 and NCT01165229), were published in the Journal of Infectious Diseases.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top